Morgan Stanley Maintains Equal-Weight on Genmab, Lowers Price Target to $56

Benzinga · 1d ago
Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and lowers the price target from $57 to $56.